LifeNet Health Introduces Dermacell® Porous for Effective Wound Management Nationwide

Innovative Solutions in Wound Management

In the United States, over 38 million individuals are living with diabetes, with a staggering 95% diagnosed with type 2 diabetes. This prevalent health crisis significantly complicates wound care, particularly in underserved communities where access to quality healthcare is limited. Addressing this urgent issue, LifeNet Health, a leader in regenerative medicine, has unveiled their latest product: Dermacell® Porous. This innovative solution sets a new standard in wound management, making it more accessible for healthcare providers and patients across the nation.

A Game Changer in Chronic Wound Care

Dermacell® Porous is designed with the unique needs of chronic wound patients in mind. It can facilitate wound closure in just four applications or fewer, positioning it as one of the most efficient skin substitute grafts available. As of January 1, 2026, Dermacell® Porous will be included in the Medicare's Local Coverage Determinations, thus expanding its reach and affordability for potential users.

Known for its thin and durable structure, Dermacell® Porous utilizes LifeNet Health's proprietary Matracell® technology to enhance its performance. Unlike many existing products, Dermacell® Porous retains the integral components of donor tissue, such as collagens, elastin, proteins, and growth factors, ensuring a biohospitable environment conducive to healing. Furthermore, the product undergoes advanced sterilization processes, validating its safety for both patients and healthcare professionals.

Dr. Loan Lam, the Medical Director of Wound Services at United Vein Vascular Centers, was among the first to implement Dermacell® Porous in clinical settings. He reported impressive outcomes, stating, "With Dermacell Porous, not only does a thin intact dermal structure provide a good initial physical scaffold, but we see faster incorporation and better integration, and more predictable healing."

Evidence-Based Results

Clinical studies reflecting the effectiveness of Dermacell® Porous support Dr. Lam's observations. Research has shown a 135% higher healing rate and a remarkable 148% greater wound reduction compared to standard dressings. Moreover, specific studies involving Wagner 3 and 4 wounds exhibited an 84% lower amputation rate for participants using Dermacell® Porous, signaling a transformative impact on patient care.

Innovations like Dermacell® Porous are essential, especially in light of the increasing healthcare challenges faced by diabetic patients. Daniel Osborne, Chief Growth Officer at LifeNet Health, highlighted the company's commitment to innovation, stating, "At LifeNet Health, our goal is to transform patients' lives through innovation and compassionate care. The introduction of Dermacell Porous is a testament to our commitment to addressing critical healthcare challenges and ensuring greater access to regenerative wound care solutions."

Ready for Use and Storage

One of the most advantageous features of Dermacell® Porous is its straightforward application. It is ready for use straight from the package, eliminating additional preparation and facilitating easy storage. Designed to remain stable at room temperature, it enhances logistical efficiency for healthcare providers, simplifying the wound management process.

Conclusion

LifeNet Health's Dermacell® Porous represents a significant advancement in wound care, delivering hope and healing to millions of diabetes patients across America. With its promising results in clinical settings, commitment to improving patient outcomes, and increased accessibility, Dermacell® Porous is poised to change the landscape of regenerative medicine and wound management for the better.

This revolutionary solution is an important step in ensuring that quality wound care is available to all, particularly in underserved communities where the need is most critical. LifeNet Health continues to honor the essence of healing through innovation, helping transform the lives of those challenged by diabetes and its complications.